A Novartis and Ionis pelacarsen setback is reigniting questions about the next steps for lipoprotein(a)–lowering therapies and the broader cardiovascular strategy built around them. The report describes how pelacarsen failed to protect heart health in a large clinical trial despite lowering Lp(a), underscoring uncertainty about whether biochemical target engagement translates into clinical benefit. The development matters for biotech pipeline prioritization because it challenges assumptions in a class of heart medicines that have attracted significant attention. It also raises the bar for future Lp(a) programs to demonstrate outcomes rather than biomarker movement alone. For drug developers, the key takeaway is heightened scrutiny on endpoints and mechanistic plausibility as the field continues to test how to translate target biology into patient benefit.